Jun-Ichi Kira

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/146897/publications.pdf

Version: 2024-02-01

324 papers 8,951 citations

41344 49 h-index 79 g-index

348 all docs 348 docs citations

348 times ranked

8696 citing authors

#	Article	IF	CITATIONS
1	Multiple sclerosis in the Japanese population. Lancet Neurology, The, 2003, 2, 117-127.	10.2	382
2	Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. Brain, 2005, 128, 988-1002.	7.6	316
3	Western versus asian types of multiple sclerosis: Immunogenetically and clinically distinct disorders. Annals of Neurology, 1996, 40, 569-574.	5. 3	283
4	Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese. Brain, 2007, 130, 1206-1223.	7.6	249
5	Characteristic Cerebrospinal Fluid Cytokine/Chemokine Profiles in Neuromyelitis Optica, Relapsing Remitting or Primary Progressive Multiple Sclerosis. PLoS ONE, 2013, 8, e61835.	2.5	184
6	Increased HTLVâ€I proviral DNA in HTLVâ€I–associated myelopathy: A quantitative polymerase chain reaction study. Annals of Neurology, 1991, 29, 194-201.	5.3	165
7	HLA-DPB1*0501-associated opticospinal multiple sclerosis: Clinical, neuroimaging and immunogenetic studies. Brain, 1999, 122, 1689-1696.	7.6	163
8	Anti-neurofascin antibody in patients with combined central and peripheral demyelination. Neurology, 2013, 81, 714-722.	1.1	157
9	Paranodal dissection in chronic inflammatory demyelinating polyneuropathy with anti-neurofascin-155 and anti-contactin-1 antibodies. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 465-473.	1.9	151
10	Characterization of IgG4 antiâ€neurofascin 155 antibodyâ€positive polyneuropathy. Annals of Clinical and Translational Neurology, 2015, 2, 960-971.	3.7	148
11	Apomorphine treatment in Alzheimer mice promoting amyloidâ€Î² degradation. Annals of Neurology, 2011, 69, 248-256.	5.3	134
12	Histopathologic Analysis of Retrieved Thrombi Associated With Successful Reperfusion After Acute Stroke Thrombectomy. Stroke, 2016, 47, 3035-3037.	2.0	133
13	A nationwide survey of hypertrophic pachymeningitis in Japan. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 732-739.	1.9	131
14	Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD. Neurology, 2019, 93, e1299-e1311.	1.1	129
15	Targeted lipidomics reveals mPGES-1-PGE2 as a therapeutic target for multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 21807-21812.	7.1	123
16	Distinct genetic and infectious profiles in Japanese neuromyelitis optica patients according to anti-aquaporin 4 antibody status. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 29-34.	1.9	118
17	Worldwide Incidence and Prevalence of Neuromyelitis Optica. Neurology, 2021, 96, 59-77.	1.1	101
18	Helicobacter pylori infection is a potential protective factor against conventional multiple sclerosis in the Japanese population. Journal of Neuroimmunology, 2007, 184, 227-231.	2.3	99

#	Article	IF	CITATIONS
19	CSF chemokine alterations related to the clinical course of amyotrophic lateral sclerosis. Journal of Neuroimmunology, 2010, 222, 76-81.	2.3	98
20	Presence of HTLV-I proviral DNA in central nervous system of patients with HTLV-I-associated myelopathy. Annals of Neurology, 1992, 31, 39-45.	5.3	92
21	Multiple system degeneration with basophilic inclusions in Japanese ALS patients with FUS mutation. Acta Neuropathologica, 2010, 119, 355-364.	7.7	90
22	Upregulation of vascular growth factors in multiple sclerosis: Correlation with MRI findings. Journal of the Neurological Sciences, 2006, 243, 21-30.	0.6	89
23	Intrathecal Upregulation of Granulocyte Colony Stimulating Factor and Its Neuroprotective Actions on Motor Neurons in Amyotrophic Lateral Sclerosis. Journal of Neuropathology and Experimental Neurology, 2006, 65, 816-825.	1.7	89
24	Connexin 43 Astrocytopathy Linked to Rapidly Progressive Multiple Sclerosis and Neuromyelitis Optica. PLoS ONE, 2013, 8, e72919.	2.5	89
25	Increases in helper induced T cells and activated T cells in HTLV-l-associated myelopathy. Annals of Neurology, 1989, 26, 257-262.	5.3	86
26	Mutations in <i>MME</i> cause an autosomalâ€recessive Charcot–Marie–Tooth disease type 2. Annals of Neurology, 2016, 79, 659-672.	5.3	82
27	Association of anti- <i>Helicobacter pylori</i> neutrophil-activating protein antibody response with anti-aquaporin-4 autoimmunity in Japanese patients with multiple sclerosis and neuromyelitis optica. Multiple Sclerosis Journal, 2009, 15, 1411-1421.	3.0	75
28	Neuromyelitis optica and opticospinal multiple sclerosis: Mechanisms and pathogenesis. Pathophysiology, 2011, 18, 69-79.	2.2	72
29	Connexin 30 deficiency attenuates A2 astrocyte responses and induces severe neurodegeneration in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride Parkinson's disease animal model. Journal of Neuroinflammation, 2018, 15, 227.	7.2	71
30	Acute myelitis associated with hyperlgEemia and atopic dermatitis. Journal of the Neurological Sciences, 1997, 148, 199-203.	0.6	70
31	lgG4 anti-neurofascin155 antibodies in chronic inflammatory demyelinating polyradiculoneuropathy: Clinical significance and diagnostic utility of a conventional assay. Journal of Neuroimmunology, 2016, 301, 16-22.	2.3	70
32	Safety and efficacy of thalidomide in patients with POEMS syndrome: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurology, The, 2016, 15, 1129-1137.	10.2	66
33	Genetic and Infectious Profiles of Japanese Multiple Sclerosis Patients. PLoS ONE, 2012, 7, e48592.	2.5	65
34	Apathy/depression, but not subjective fatigue, is related with cognitive dysfunction in patients with multiple sclerosis. BMC Neurology, 2014, 14, 3.	1.8	61
35	Long term, high dose interferon-alpha treatment in HTLV-I-associated myelopathy/tropical spastic paraparesis: a combined clinical, virological and immunological study. Journal of the Neurological Sciences, 1997, 147, 135-144.	0.6	60
36	Upregulation of myeloperoxidase in patients with opticospinal multiple sclerosis: Positive correlation with disease severity. Journal of Neuroimmunology, 2006, 178, 156-160.	2.3	60

#	Article	IF	CITATIONS
37	Neuromyelitis Optica and Asian Phenotype of Multiple Sclerosis. Annals of the New York Academy of Sciences, 2008, 1142, 58-71.	3.8	60
38	Peripheral Blood T Cell Dynamics Predict Relapse in Multiple Sclerosis Patients on Fingolimod. PLoS ONE, 2015, 10, e0124923.	2.5	60
39	Increased IL-13-producing T cells in ALS: Positive correlations with disease severity and progression rate. Journal of Neuroimmunology, 2007, 182, 232-235.	2.3	58
40	A nationwide survey of combined central and peripheral demyelination in Japan. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, jnnp-2014-309831.	1.9	58
41	Extensive loss of connexins in Baló's disease: evidence for an auto-antibody-independent astrocytopathy via impaired astrocyte–oligodendrocyte/myelin interaction. Acta Neuropathologica, 2012, 123, 887-900.	7.7	57
42	Reappraisal of brain MRI features in patients with multiple sclerosis and neuromyelitis optica according to anti-aquaporin-4 antibody status. Journal of the Neurological Sciences, 2010, 291, 37-43.	0.6	56
43	Changes in the clinical phenotypes of multiple sclerosis during the past 50 years in Japan. Journal of the Neurological Sciences, 1999, 166, 53-57.	0.6	55
44	Tc1/Tc2 and Th1/Th2 balance in Asian and Western types of multiple sclerosis, HTLV-l-associated myelopathy/tropical spastic paraparesis and hyperlgEaemic myelitis. Journal of Neuroimmunology, 2001, 119, 297-305.	2.3	55
45	Aquaporin-4 astrocytopathy in Baló's disease. Acta Neuropathologica, 2010, 120, 651-660.	7.7	53
46	Extensive dysregulations of oligodendrocytic and astrocytic connexins are associated with disease progression in an amyotrophic lateral sclerosis mouse model. Journal of Neuroinflammation, 2014, 11, 42.	7.2	53
47	Vitamin B12 Metabolism and Massive-Dose Methyl Vitamin B12 Therapy in Japanese Patients with Multiple Sclerosis Internal Medicine, 1994, 33, 82-86.	0.7	52
48	Intracellular accumulation of toxic turn amyloid- \hat{l}^2 is associated with endoplasmic reticulum stress in Alzheimer's disease. Current Alzheimer Research, 2013, 10, 11-20.	1.4	52
49	Hypertrophic Cranial Pachymeningitis Associated with Mixed Connective Tissue Disease; A Comparison with Idiopathic and Infectious Pachymeningitis Internal Medicine, 1993, 32, 510-512.	0.7	51
50	Th1 shift in CIDP versus Th2 shift in vasculitic neuropathy in CSF. Journal of the Neurological Sciences, 2005, 228, 75-85.	0.6	50
51	Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension. BMC Neurology, 2014, 14, 21.	1.8	50
52	Myelitis with atopic diathesis: a nationwide survey of 79 cases in Japan. Journal of the Neurological Sciences, 2003, 209, 5-11.	0.6	49
53	Autoimmunity in neuromyelitis optica and opticospinal multiple sclerosis: Astrocytopathy as a common denominator in demyelinating disorders. Journal of the Neurological Sciences, 2011, 311, 69-77.	0.6	49
54	Chronic Inflammatory Demyelinating Polyneuropathy With Concurrent Membranous Nephropathy: An Anti-paranode and Podocyte Protein Antibody Study and Literature Survey. Frontiers in Neurology, 2018, 9, 997.	2.4	49

#	Article	IF	CITATIONS
55	Hyperprolactinemia in Optico-spinal Multiple Sclerosis Internal Medicine, 2000, 39, 296-299.	0.7	48
56	Clinical, immunological and MRI features of myelitis with atopic dermatitis (atopic myelitis). Journal of the Neurological Sciences, 1999, 162, 56-61.	0.6	45
57	Restoration of microglial function by granulocyte-colony stimulating factor in ALS model mice. Journal of Neuroimmunology, 2010, 229, 51-62.	2.3	44
58	Spinal cord lesions of myelitis with hyperlgEemia and mite antigen specific IgE (atopic myelitis) manifest eosinophilic inflammation. Journal of the Neurological Sciences, 2001, 183, 73-78.	0.6	43
59	A case of hereditary diffuse leukoencephalopathy with axonal spheroids caused by a de novo mutation in $\langle i \rangle$ CSF1R $\langle i \rangle$ masquerading as primary progressive multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 1367-1370.	3.0	42
60	Nationwide epidemiological study of neuromyelitis optica in Japan. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 667-668.	1.9	42
61	Reappraisal of Aquaporinâ€4 Astrocytopathy in Asian Neuromyelitis Optica and Multiple Sclerosis Patients. Brain Pathology, 2011, 21, 516-532.	4.1	41
62	Intracellular Accumulation of Toxic Turn Amyloid- \hat{l}^2 is Associated with Endoplasmic Reticulum Stress in Alzheimer $\hat{a} \in \mathbb{N}$ s Disease. Current Alzheimer Research, 2013, 10, 11-20.	1.4	41
63	Allergic Inflammation Leads to Neuropathic Pain via Glial Cell Activation. Journal of Neuroscience, 2016, 36, 11929-11945.	3.6	40
64	Th1 cells downregulate connexin 43 gap junctions in astrocytes via microglial activation. Scientific Reports, 2016, 6, 38387.	3.3	38
65	Genetic and Infectious Profiles Influence Cerebrospinal Fluid IgG Abnormality in Japanese Multiple Sclerosis Patients. PLoS ONE, 2014, 9, e95367.	2.5	37
66	Ceramide induces apoptosis to immature cerebellar granule cells in culture. Neurochemical Research, 1999, 24, 685-690.	3.3	36
67	Flow cytometric differentiation of Asian and Western types of multiple sclerosis, HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and hyperIgEaemic myelitis by analyses of memory CD4 positive T cell subsets and NK cell subsets. Journal of the Neurological Sciences, 2000, 177, 24-31.	0.6	36
68	Quantitative assays for anti-aquaporin-4 antibody with subclass analysis in neuromyelitis optica. Multiple Sclerosis Journal, 2012, 18, 1541-1551.	3.0	36
69	Sequence heterogeneity of HTLV-I proviral DNA in the central nervous system of patients with HTLV-I-associated myelopathy. Annals of Neurology, 1994, 36, 149-156.	5.3	35
70	Effects of stimulus orientation on spatial frequency function of the visual evoked potential. Experimental Brain Research, 2000, 131, 121-125.	1.5	35
71	Eosinophilic myelitis associated with atopic diathesis: a combined neuroimaging and histopathological study. Acta Neuropathologica, 2003, 105, 289-295.	7.7	35
72	Astrocytopathy in Baló's disease. Multiple Sclerosis Journal, 2011, 17, 771-779.	3.0	35

#	Article	IF	CITATIONS
73	Anti-neurofascin autoantibody and demyelination. Neurochemistry International, 2019, 130, 104360.	3.8	35
74	Heterogeneity and continuum of multiple sclerosis phenotypes in Japanese according to the results of the fourth nationwide survey. Journal of the Neurological Sciences, 2009, 280, 22-28.	0.6	34
75	TAR DNA-binding protein 43 pathology in a case clinically diagnosed with facial-onset sensory and motor neuronopathy syndrome: An autopsied case report and a review of the literature. Journal of the Neurological Sciences, 2013, 332, 148-153.	0.6	34
76	Copy number variations in multiple sclerosis and neuromyelitis optica. Annals of Neurology, 2015, 78, 762-774.	5.3	34
77	Unexpected exacerbations following initiation of disease-modifying drugs in neuromyelitis optica spectrum disorder: Which factor is responsible, anti-aquaporin 4 antibodies, B cells, Th1 cells, Th2 cells, Th17 cells, or others?. Multiple Sclerosis Journal, 2017, 23, 1300-1302.	3.0	33
78	Heterogeneity and continuum of multiple sclerosis in Japanese according to magnetic resonance imaging findings. Journal of the Neurological Sciences, 2008, 266, 115-125.	0.6	32
79	Decreased serum vitamin D levels in Japanese patients with multiple sclerosis. Journal of Neuroimmunology, 2015, 279, 40-45.	2.3	32
80	Efficacy of intravenous methylprednisolone pulse therapy in patients with multiple sclerosis and neuromyelitis optica. Multiple Sclerosis Journal, 2016, 22, 1337-1348.	3.0	32
81	Choroid Plexus Volume in Multiple Sclerosis vs Neuromyelitis Optica Spectrum Disorder. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	32
82	Evaluation of chronic inflammatory demyelinating polyneuropathy: 3D nerve-sheath signal increased with inked rest-tissue rapid acquisition of relaxation enhancement imaging (3D SHINKEI). European Radiology, 2017, 27, 447-453.	4.5	31
83	Novel disease-modifying anti-rheumatic drug iguratimod suppresses chronic experimental autoimmune encephalomyelitis by down-regulating activation of macrophages/microglia through an NF-κB pathway. Scientific Reports, 2018, 8, 1933.	3.3	31
84	Insulin deficiency promotes formation of toxic amyloid-l ² 42 conformer co-aggregating with hyper-phosphorylated tau oligomer in an Alzheimer's disease model. Neurobiology of Disease, 2020, 137, 104739.	4.4	31
85	Oligodendroglial connexin 47 regulates neuroinflammation upon autoimmune demyelination in a novel mouse model of multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 2160-2169.	7.1	31
86	First diagnostic criteria for atopic myelitis with special reference to discrimination from myelitis-onset multiple sclerosis. Journal of the Neurological Sciences, 2012, 316, 30-35.	0.6	30
87	Latitude and HLA-DRB1*04:05 independently influence disease severity in Japanese multiple sclerosis: a cross-sectional study. Journal of Neuroinflammation, 2016, 13, 239.	7.2	30
88	Clinicopathologic Features of Oculopharyngodistal Myopathy With <i>LRP12 </i> CGG Repeat Expansions Compared With Other Oculopharyngodistal Myopathy Subtypes. JAMA Neurology, 2021, 78, 853.	9.0	30
89	Amino Acid Sequence of Porcine Myelin Basic Protein. Journal of Neurochemistry, 1985, 44, 134-142.	3.9	29
90	Immunohistochemical analysis of spinal cord lesions in amyotrophic lateral sclerosis using microtubule-associated protein 2 (MAP2) antibodies. Acta Neuropathologica, 1999, 97, 13-21.	7.7	29

#	Article	IF	CITATIONS
91	Involvement of lysosomal storage-induced p38 MAP kinase activation in the overproduction of nitric oxide by microglia in cathepsin D-deficient mice. Molecular and Cellular Neurosciences, 2007, 35, 573-584.	2.2	29
92	Pre-admission CHADS2, CHA2DS2-VASc, and R2CHADS2 Scores on Severity and Functional Outcome in Acute Ischemic Stroke with Atrial Fibrillation. Journal of Stroke and Cerebrovascular Diseases, 2015, 24, 1629-1635.	1.6	29
93	Early strong intrathecal inflammation in cerebellar type multiple system atrophy by cerebrospinal fluid cytokine/chemokine profiles: a case control study. Journal of Neuroinflammation, 2017, 14, 89.	7.2	29
94	Age-related changes across the primary and secondary somatosensory areas: An analysis of neuromagnetic oscillatory activities. Clinical Neurophysiology, 2014, 125, 1021-1029.	1.5	28
95	Pharmacological activation of SERCA ameliorates dystrophic phenotypes in dystrophin-deficient <i>mdx</i> mice. Human Molecular Genetics, 2021, 30, 1006-1019.	2.9	28
96	Increased IL-13 but not IL-5 production by CD4-positive T cells and CD8-positive T cells in multiple sclerosis during relapse phase. Journal of the Neurological Sciences, 2002, 201, 45-51.	0.6	27
97	Facial onset sensory and motor neuronopathy (FOSMN) syndrome responding to immunotherapies. Journal of the Neurological Sciences, 2008, 275, 157-158.	0.6	27
98	Parallel fluctuation of anti-neurofascin 155 antibody levels with clinico-electrophysiological findings in patients with chronic inflammatory demyelinating polyradiculoneuropathy. Journal of the Neurological Sciences, 2018, 384, 107-112.	0.6	27
99	Functional connectivity change between posterior cingulate cortex and ventral attention network relates to the impairment of orientation for time in Alzheimer's disease patients. Brain Imaging and Behavior, 2019, 13, 154-161.	2.1	27
100	Platelet reactivity and hemorrhage risk in neurointerventional procedures under dual antiplatelet therapy. Journal of NeuroInterventional Surgery, 2016, 8, 949-953.	3.3	26
101	Early and extensive spinal white matter involvement in neuromyelitis optica. Brain Pathology, 2017, 27, 249-265.	4.1	26
102	ELectron microscopic abnormality and therapeutic efficacy in chronic inflammatory demyelinating polyneuropathy with antiâ€neurofascin155 immunoglobulin G4 antibody. Muscle and Nerve, 2018, 57, 498-502.	2.2	26
103	Connexin 30 Deficiency Attenuates Chronic but Not Acute Phases of Experimental Autoimmune Encephalomyelitis Through Induction of Neuroprotective Microglia. Frontiers in Immunology, 2018, 9, 2588.	4.8	26
104	Apomorphine Therapy for Neuronal Insulin Resistance in a Mouse Model of Alzheimer's Disease. Journal of Alzheimer's Disease, 2017, 58, 1151-1161.	2.6	25
105	Expression of the lysosome-associated membrane proteins in myopathies with rimmed vacuoles. Acta Neuropathologica, 2001, 101, 579-584.	7.7	24
106	Association of susceptibility to multiple sclerosis in Southern Han Chinese with HLA-DRB1, -DPB1 alleles and DRB1-DPB1 haplotypes: distinct from other populations. Multiple Sclerosis Journal, 2009, 15, 1422-1430.	3.0	24
107	Multimodality-evoked potential study of anti-aquaporin-4 antibody-positive and -negative multiple sclerosis patients. Journal of the Neurological Sciences, 2009, 281, 34-40.	0.6	24
108	Clinical features and treatment status of adult myasthenia gravis in <scp>J</scp> apan. Clinical and Experimental Neuroimmunology, 2014, 5, 84-91.	1.0	24

#	Article	IF	Citations
109	Interleukin 2 receptor î± chain gene polymorphisms and risks of multiple sclerosis and neuromyelitis optica in southern Japanese. Journal of the Neurological Sciences, 2014, 337, 147-150.	0.6	24
110	Efficacy, safety, and pharmacokinetics of natalizumab in Japanese multiple sclerosis patients: A double-blind, randomized controlled trial and open-label pharmacokinetic study. Multiple Sclerosis and Related Disorders, 2017, 11, 25-31.	2.0	24
111	Corpus Callosum Atrophy in Patients with Hereditary Diffuse Leukoencephalopathy with Neuroaxonal Spheroids: An MRI-based Study. Internal Medicine, 2014, 53, 21-27.	0.7	23
112	Necklace cytoplasmic bodies in hereditary myopathy with early respiratory failure. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 483-489.	1.9	23
113	Efficacy and Safety of Rituximab in Refractory CIDP With or Without IgG4 Autoantibodies (RECIPE): Protocol for a Double-Blind, Randomized, Placebo-Controlled Clinical Trial. JMIR Research Protocols, 2020, 9, e17117.	1.0	23
114	Preferential neurodegeneration in the cervical spinal cord of progressive supranuclear palsy. Acta Neuropathologica, 1999, 97, 577-584.	7.7	22
115	Time-dependent cytokine deviation toward the Th2 side in Japanese multiple sclerosis patients with interferon beta-1b. Journal of the Neurological Sciences, 2004, 222, 65-73.	0.6	22
116	Helicobacter pylori infection and demyelinating disease of the central nervous system. Journal of Neuroimmunology, 2019, 329, 14-19.	2.3	22
117	Early postnatal allergic airway inflammation induces dystrophic microglia leading to excitatory postsynaptic surplus and autism-like behavior. Brain, Behavior, and Immunity, 2021, 95, 362-380.	4.1	22
118	A Potential VEP Biomarker for Mild Cognitive Impairment: Evidence from Selective Visual Deficit of Higher-Level Dorsal Pathway. Journal of Alzheimer's Disease, 2016, 53, 661-676.	2.6	21
119	Cathepsin E in neutrophils contributes to the generation of neuropathic pain in experimental autoimmune encephalomyelitis. Pain, 2019, 160, 2050-2062.	4.2	21
120	Hepatitis C Virus Associated Cryoglobulinemic Neuropathy Successfully Treated with Plasma Exchange. Artificial Organs, 1995, 19, 334-338.	1.9	20
121	Atopic myelitis with focal amyotrophy: A possible link to Hopkins syndrome. Journal of the Neurological Sciences, 2008, 269, 143-151.	0.6	20
122	Frequency of Chronic Headaches in Japanese Patients With Multiple Sclerosis: With Special Reference to Opticospinal and Common Forms of Multiple Sclerosis. Headache, 2009, 49, 1513-1520.	3.9	20
123	A comparison of brain magnetic resonance imaging lesions in multiple sclerosis by race with reference to disability progression. Journal of Neuroinflammation, 2018, 15, 255.	7.2	20
124	A Novel Autoantibody against Plexin <scp>D</scp> 1 in Patients with Neuropathic Pain. Annals of Neurology, 2018, 84, 208-224.	5.3	20
125	Genetic factors for susceptibility to and manifestations of neuromyelitis optica. Annals of Clinical and Translational Neurology, 2020, 7, 2082-2093.	3.7	20
126	Reduced Post-ischemic Brain Injury in Transient Receptor Potential Vanilloid 4 Knockout Mice. Frontiers in Neuroscience, 2020, 14, 453.	2.8	20

#	Article	IF	CITATIONS
127	Anti-Neurofascin 155 Antibody-Positive Chronic Inflammatory Demyelinating Polyneuropathy/Combined Central and Peripheral Demyelination: Strategies for Diagnosis and Treatment Based on the Disease Mechanism. Frontiers in Neurology, 2021, 12, 665136.	2.4	20
128	Long-term efficacy and safety of fingolimod in Japanese patients with relapsing multiple sclerosis: 3-year results of the phase 2 extension study. BMC Neurology, 2017, 17, 17.	1.8	19
129	HLA genotype-clinical phenotype correlations in multiple sclerosis and neuromyelitis optica spectrum disorders based on Japan MS/NMOSD Biobank data. Scientific Reports, 2021, 11, 607.	3.3	19
130	Peptide-Based Molecular Analyses of <i>HLA class II </i> Diseases. International Reviews of Immunology, 1998, 17, 229-262.	3.3	18
131	A case of synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome presenting with hypertrophic pachymeningitis. Journal of the Neurological Sciences, 2015, 349, 229-231.	0.6	18
132	Unique HLA haplotype associations in lgG4 anti-neurofascin 155 antibody-positive chronic inflammatory demyelinating polyneuropathy. Journal of Neuroimmunology, 2020, 339, 577139.	2.3	18
133	A Prospective, Multicenter, Randomized Phase II Study to Evaluate the Efficacy and Safety of Eculizumab in Patients with Guillain-Barré Syndrome (GBS): Protocol of Japanese Eculizumab Trial for GBS (JET-GBS). JMIR Research Protocols, 2016, 5, e210.	1.0	18
134	Effect of immunotherapy in myelitis with atopic diathesis. Journal of the Neurological Sciences, 2004, 227, 39-47.	0.6	17
135	CD30 ligand is a new therapeutic target for central nervous system autoimmunity. Journal of Autoimmunity, 2015, 57, 14-23.	6.5	17
136	Lumbar plexus in patients with chronic inflammatory demyelinating polyneuropathy: Evaluation with 3D nerve-sheath signal increased with inked rest-tissue rapid acquisition of relaxation enhancement imaging (3D SHINKEI). European Journal of Radiology, 2017, 93, 95-99.	2.6	17
137	Improving treatment times for patients with in-hospital stroke using a standardized protocol. Journal of the Neurological Sciences, 2017, 381, 68-73.	0.6	17
138	Differential activation of neuronal and glial <scp>STAT</scp> 3 in the spinal cord of the <i><scp>SOD</scp>1</i> ^{<i>G93A</i>} mouse model of amyotrophic lateral sclerosis. European Journal of Neuroscience, 2017, 46, 2001-2014.	2.6	17
139	Connexins in neuromyelitis optica: a link between astrocytopathy and demyelination. Brain, 2020, 143, 2721-2732.	7.6	17
140	MUTYH Actively Contributes to Microglial Activation and Impaired Neurogenesis in the Pathogenesis of Alzheimer's Disease. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-30.	4.0	17
141	Multiple sclerosis with mite antigen-specific IgE. Journal of the Neurological Sciences, 1998, 157, 138-142.	0.6	16
142	Recurrent Hopkin's syndrome: A case report and review of the literature. Journal of the Neurological Sciences, 2010, 297, 89-91.	0.6	16
143	Validation of the Brief International Cognitive Assessment for Multiple Sclerosis in Japan. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2017, 3, 205521731774897.	1.0	16
144	MOG antibody disease manifesting as progressive cognitive deterioration and behavioral changes with primary central nervous system vasculitis. Multiple Sclerosis and Related Disorders, 2019, 30, 48-50.	2.0	16

#	Article	IF	CITATIONS
145	Multiple Sclerosis. Advances in Experimental Medicine and Biology, 2019, 1190, 217-247.	1.6	16
146	Simultaneous MR neurography and apparent T2 mapping in brachial plexus: Evaluation of patients with chronic inflammatory demyelinating polyradiculoneuropathy. Magnetic Resonance Imaging, 2019, 55, 112-117.	1.8	16
147	Spinal cord involvement by atrophy and associations with disability are different between multiple sclerosis and neuromyelitis optica spectrum disorder. European Journal of Neurology, 2020, 27, 92-99.	3.3	16
148	Platelet-activating factor receptor gene polymorphism in Japanese patients with multiple sclerosis. Journal of Neuroimmunology, 2005, 161, 195-198.	2.3	15
149	Genetic and environmental backgrounds responsible for the changes in the phenotype of MS in Japanese subjects. Multiple Sclerosis and Related Disorders, 2012, 1, 188-195.	2.0	15
150	Differences between predictive factors for early neurological deterioration due to hemorrhagic and ischemic insults following intravenous recombinant tissue plasminogen activator. Journal of Thrombosis and Thrombolysis, 2020, 49, 545-550.	2.1	15
151	Atopy and Neural Damage Internal Medicine, 2002, 41, 169-174.	0.7	14
152	Japanese POEMS syndrome with Thalidomide (J-POST) Trial: study protocol for a phase II/III multicentre, randomised, double-blind, placebo-controlled trial. BMJ Open, 2015, 5, e007330-e007330.	1.9	14
153	Neuromagnetic evidence for hippocampal modulation of auditory processing. Neurolmage, 2016, 124, 256-266.	4.2	14
154	Grand Total EEG Score Can Differentiate Parkinson's Disease From Parkinson-Related Disorders. Frontiers in Neurology, 2019, 10, 398.	2.4	14
155	Latitude and HLA-DRB1 alleles independently affect the emergence of cerebrospinal fluid IgG abnormality in multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 1112-1120.	3.0	13
156	HLA-DRB1*04:05 allele is associated with intracortical lesions on three-dimensional double inversion recovery images in Japanese patients with multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 710-720.	3.0	13
157	Optic, trigeminal, and facial neuropathy related to antiâ€neurofascin 155 antibody. Annals of Clinical and Translational Neurology, 2020, 7, 2297-2309.	3.7	13
158	Disconnection of the right superior parietal lobule from the precuneus is associated with memory impairment in oldest-old Alzheimer's disease patients. Heliyon, 2020, 6, e04516.	3.2	13
159	Activated T cells in HTLV-I-associated myelopathy: Autologous mixed lymphocyte reaction. Annals of Neurology, 1989, 26, 398-401.	5.3	12
160	Very-Long-Chain Fatty Acid Metabolism in Adrenoleukodystrophy Protein-Deficient Mice. Cell Biochemistry and Biophysics, 2000, 32, 239-246.	1.8	12
161	Platelet-activating factor acetylhydrolase gene polymorphism and its activity in Japanese patients with multiple sclerosis. Journal of Neuroimmunology, 2004, 150, 150-156.	2.3	12
162	Lumbar plexus in patients with chronic inflammatory demyelinating polyradiculoneuropathy: evaluation with simultaneous <i>T</i> ₂ mapping and neurography method with SHINKEI. British Journal of Radiology, 2018, 91, 20180501.	2.2	12

#	Article	lF	CITATIONS
163	Environmental risk factors for multiple sclerosis in Japanese people. Multiple Sclerosis and Related Disorders, 2020, 38, 101872.	2.0	12
164	Effect of ofatumumab versus placebo in relapsing multiple sclerosis patients from Japan and Russia: Phase 2 APOLITOS study. Multiple Sclerosis Journal, 2022, 28, 1229-1238.	3.0	12
165	Myelitis Associated with Atopic Disorders in Japan: A Retrospective Clinical Study of the Past 20 Years Internal Medicine, 2001, 40, 613-619.	0.7	11
166	Comparison of the Clinical Courses of the Opticospinal and Conventional Forms of Multiple Sclerosis in Japan. Internal Medicine, 2005, 44, 934-938.	0.7	11
167	Anterior periventricular linear lesions in optic-spinal multiple sclerosis: a combined neuroimaging and neuropathological study. Multiple Sclerosis Journal, 2008, 14, 343-353.	3.0	11
168	Clinical Relevance of Serum Aquaporin-4 Antibody Levels in Neuromyelitis Optica. Neurochemical Research, 2013, 38, 997-1001.	3.3	11
169	Restoration of a Conduction Block after the Long-term Treatment of CIDP with Anti-neurofascin 155 Antibodies: Follow-up of a Case over 23 Years. Internal Medicine, 2018, 57, 2061-2066.	0.7	11
170	Intrathecal cytokine profile in neuropathy with antiâ€neurofascin 155 antibody. Annals of Clinical and Translational Neurology, 2019, 6, 2304-2316.	3.7	11
171	A novel model for treatment of hypertrophic pachymeningitis. Annals of Clinical and Translational Neurology, 2019, 6, 431-444.	3.7	11
172	Distinct microglial and macrophage distribution patterns in the concentric and lamellar lesions in $Bal\tilde{A}^{3}$'s disease and neuromyelitis optica spectrum disorders. Brain Pathology, 2020, 30, 1144-1157.	4.1	11
173	Impact of thrombus migration on clinical outcomes in patients with internal carotid artery occlusions and patent middle cerebral artery. Journal of the Neurological Sciences, 2020, 412, 116737.	0.6	11
174	A new clustering method identifies multiple sclerosisâ€specific T ell receptors. Annals of Clinical and Translational Neurology, 2021, 8, 163-176.	3.7	11
175	Tissue Binding Patterns and In Vitro Effects of Campylobacter jejuni DNA-Binding Protein from Starved Cells. Neurochemical Research, 2011, 36, 58-66.	3.3	10
176	Intramuscular interferon beta-1a is effective in Japanese patients with relapsing–remitting multiple sclerosis: a pre-treatment versus treatment comparison study of gadolinium-enhanced MRI brain lesions. Multiple Sclerosis Journal, 2012, 18, 1782-1790.	3.0	10
177	Antiâ€ <scp>KIR</scp> 4.1 antibodies in <scp>J</scp> apanese patients with idiopathic central nervous system demyelinating diseases. Clinical and Experimental Neuroimmunology, 2013, 4, 241-242.	1.0	10
178	Cerebral blood flow laterality derived from arterial spin labeling as a biomarker for assessing the disease severity of parkinson's disease. Journal of Magnetic Resonance Imaging, 2017, 45, 1821-1826.	3.4	10
179	Duplication and deletion upstream of <i>LMNB1</i> in autosomal dominant adult-onset leukodystrophy. Neurology: Genetics, 2018, 4, e292.	1.9	10
180	Association of Decreased Percentage of $\hat{V}(2+\hat{V}(3))$ + $\hat{V}(3)$ T Cells With Disease Severity in Multiple Sclerosis. Frontiers in Immunology, 2018, 9, 748.	4.8	10

#	Article	IF	Citations
181	Cerebrospinal fluid cytokine/chemokine/growth factor profiles in idiopathic hypertrophic pachymeningitis. Journal of Neuroimmunology, 2019, 330, 38-43.	2.3	10
182	Novel Neuropathic Pain Mechanisms Associated With Allergic Inflammation. Frontiers in Neurology, 2019, 10, 1337.	2.4	10
183	Accumulation of Astrocytic Aquaporin 4 and Aquaporin 1 in Prion Protein Plaques. Journal of Neuropathology and Experimental Neurology, 2020, 79, 419-429.	1.7	10
184	Antiplexin D1 Antibodies Relate to Small Fiber Neuropathy and Induce Neuropathic Pain in Animals. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	10
185	High Incidence of Subclinical Peripheral Neuropathy in Myelitis with HyperlgEaemia and Mite Antigen-specific IgE (Atopic Myelitis): An Electrophysiological Study Internal Medicine, 2002, 41, 684-691.	0.7	9
186	Presence of IgE Antibodies to Bacterial Superantigens and Increased IL-13-Producing T Cells in Myelitic Patients with Atopic Diathesis. International Archives of Allergy and Immunology, 2004, 134, 41-48.	2.1	9
187	Induction of paranodal myelin detachment and sodium channel loss in vivo by Campylobacter jejuni DNA-binding protein from starved cells (C-Dps) in myelinated nerve fibers. Journal of the Neurological Sciences, 2010, 288, 54-62.	0.6	9
188	A <i>NOTCH4</i> missense mutation confers resistance to multiple sclerosis in Japanese. Multiple Sclerosis Journal, 2013, 19, 1696-1703.	3.0	9
189	Efficacy of methylprednisolone pulse therapy for acute relapse in <scp>J</scp> apanese patients with multiple sclerosis and neuromyelitis optica: A multicenter retrospective analysis – 1. Whole group analysis. Clinical and Experimental Neuroimmunology, 2013, 4, 305-317.	1.0	9
190	Association of cognitive impairment with magnetic resonance imaging findings and social activities in patients with multiple sclerosis. Clinical and Experimental Neuroimmunology, 2014, 5, 328-335.	1.0	9
191	The presence of HTLV-I proviral DNA in the central nervous system of patients with HTLV-I-associated myelopathy/tropical spastic paraparesis. Molecular Neurobiology, 1994, 8, 139-145.	4.0	8
192	Genetic and environmental factors underlying the rapid changes in epidemiological and clinical features of multiple sclerosis and neuromyelitis optica in <scp>J</scp> apanese. Clinical and Experimental Neuroimmunology, 2013, 4, 261-273.	1.0	8
193	Long-term efficacy and safety of intramuscular interferon beta-1a: Randomized postmarketing trial of two dosing regimens in Japanese patients with relapsing-remitting multiple sclerosis. Multiple Sclerosis and Related Disorders, 2016, 7, 102-108.	2.0	8
194	A novel mutation in FGD4 causes Charcot–Marie–Tooth disease type 4H with cranial nerve involvement. Neuromuscular Disorders, 2017, 27, 959-961.	0.6	8
195	Intractable axonal neuropathy with multifocal peripheral nerve swelling in neuromyelitis optica spectrum disorders: A case report. Multiple Sclerosis and Related Disorders, 2019, 35, 16-18.	2.0	8
196	Brain gray matter astroglia-specific connexin 43 ablation attenuates spinal cord inflammatory demyelination. Journal of Neuroinflammation, 2021, 18, 126.	7.2	8
197	Clearance of peripheral nerve misfolded mutant protein by infiltrated macrophages correlates with motor neuron disease progression. Scientific Reports, 2021, 11, 16438.	3.3	8
198	HLA-DPB1*0201 is associated with susceptibility to atopic myelitis in Japanese. Journal of Neuroimmunology, 2012, 251, 110-113.	2.3	7

#	Article	IF	CITATIONS
199	Myopathy in autoimmune polyendocrinopathy―candidiasisâ€ectodermal dystrophy. Muscle and Nerve, 2012, 45, 904-908.	2.2	7
200	Sporadic hereditary diffuse leukoencephalopathy with axonal spheroids showing numerous lesions with restricted diffusivity caused by a novel splice site mutation in the $<$ i> $<$ scp>CSF $<$ /scp>1R $<$ /i> $<$ gene. Clinical and Experimental Neuroimmunology, 2013, 4, 76-81.	1.0	7
201	Pure dysarthria and dysarthria-facial paresis syndrome due to internal capsule and/or corona radiata infarction. BMC Neurology, 2015, 15, 184.	1.8	7
202	A Case of Central Pontine Myelinolysis Caused by Hypophosphatemia Secondary to Refeeding Syndrome. Case Reports in Neurology, 2015, 7, 196-203.	0.7	7
203	Helicobacter pyloriinfection might prove the hygiene hypothesis in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 591-592.	1.9	7
204	Therapeutic benefits of an oral vitamin B1 derivative for human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis (HAM/TSP). BMC Medicine, 2013, 11, 183.	5.5	6
205	Requirement of CD30 expression on CD4 T cells in the pathogenesis of experimental autoimmune encephalomyelitis. Journal of Neuroimmunology, 2016, 291, 39-45.	2.3	6
206	Differential involvement of vesicular and glial glutamate transporters around spinal \hat{l}_{\pm} -motoneurons in the pathogenesis of SOD1G93A mouse model of amyotrophic lateral sclerosis. Neuroscience, 2017, 356, 114-124.	2.3	6
207	Structural changes in Parkinson's disease: voxel-based morphometry and diffusion tensor imaging analyses based on 123I-MIBG uptake. European Radiology, 2017, 27, 5073-5079.	4.5	6
208	Downregulation of Neuronal and Dendritic Connexin36-Made Electrical Synapses Without Glutamatergic Axon Terminals in Spinal Anterior Horn Cells From the Early Stage of Amyotrophic Lateral Sclerosis. Frontiers in Neuroscience, 2018, 12, 894.	2.8	6
209	Hopkins syndrome following the first episode of bronchial asthma associated with enterovirus D68: a case report. BMC Neurology, 2018, 18, 71.	1.8	6
210	Long-term use of interferon- \hat{l}^2 in multiple sclerosis increases $\hat{Vl'1a^2Vl'2a^2Vl'39a^2l'13l'}$ cells that are associated with a better outcome. Journal of Neuroinflammation, 2019, 16, 179.	7.2	6
211	Discriminative clinical and neuroimaging features of motor-predominant hereditary diffuse leukoencephalopathy with axonal spheroids and primary progressive multiple sclerosis: A preliminary cross-sectional study. Multiple Sclerosis and Related Disorders, 2019, 31, 22-31.	2.0	6
212	Toxic myopathy with multiple deletions in mitochondrial DNA associated with longâ€term use of oral antiâ€viral drugs for hepatitis B: A case study. Neuropathology, 2019, 39, 162-167.	1.2	6
213	Morphological alteration of myelin-oligodendrocytes in a schizophrenic patient with 22q11.2 deletion syndrome: An autopsy study. Schizophrenia Research, 2020, 223, 353-355.	2.0	6
214	Painful trigeminal neuropathy associated with anti-Plexin D1 antibody. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, e819.	6.0	6
215	PCBP2 Is Downregulated in Degenerating Neurons and Rarely Observed in TDP-43-Positive Inclusions in Sporadic Amyotrophic Lateral Sclerosis. Journal of Neuropathology and Experimental Neurology, 2021, 80, 220-228.	1.7	6
216	Month of birth in multiple sclerosis with and without longitudinally extensive spinal cord lesions: A study of a Japanese national survey. Journal of the Neurological Sciences, 2013, 330, 67-70.	0.6	5

#	Article	IF	CITATIONS
217	Distinct genetic profiles between <scp>J</scp> apanese multiple sclerosis patients with and without <scp>B</scp> arkhof brain lesions. Clinical and Experimental Neuroimmunology, 2013, 4, 173-180.	1.0	5
218	Outcomes of pregnancy during interferon betaâ€1a therapy in Japanese patients with multiple sclerosis: Interim results of a postmarketing surveillance study. Clinical and Experimental Neuroimmunology, 2015, 6, 402-408.	1.0	5
219	Recurrent Hemorrhagic Venous Infarctions Caused by Thrombosis of a Pontine Developmental Venous Anomaly and Protein S Mutation. Journal of Stroke and Cerebrovascular Diseases, 2016, 25, e216-e217.	1.6	5
220	Dermatomyositis complicated with asymmetric peripheral neuritis on exacerbation: A case report and literature review. Clinical and Experimental Neuroimmunology, 2016, 7, 373-380.	1.0	5
221	Antibodies to myelin oligodendrocyte glycoprotein are uncommon in Japanese opticospinal multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 127-128.	3.0	5
222	q-space Myelin Map imaging: A new imaging technique for treatment evaluation in multiple sclerosis. Journal of the Neurological Sciences, 2017, 373, 358-359.	0.6	5
223	Re-emergence of a tumefactive demyelinating lesion after initiation of fingolimod therapy. Journal of the Neurological Sciences, 2017, 379, 167-168.	0.6	5
224	Slowed abduction during smooth pursuit eye movement in episodic ataxia type 2 with a novel CACNA1A mutation. Journal of the Neurological Sciences, 2017, 381, 4-6.	0.6	5
225	Short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms in NMOSD. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e447.	6.0	5
226	Oral phase dysphagia in facial onset sensory and motor neuronopathy. Brain and Behavior, 2018, 8, e00999.	2.2	5
227	Neuromagnetic correlates of hemispheric specialization for face and word recognition. Neuroscience Research, 2020, 156, 108-116.	1.9	5
228	Modified diffusion-weighted imaging-Alberta Stroke Program Early Computed Tomography Score including deep white matter lesions predicts symptomatic intracerebral hemorrhage following intravenous thrombolysis. Journal of Thrombosis and Thrombolysis, 2020, 50, 174-180.	2.1	5
229	Early decrease in intermediate monocytes in peripheral blood is characteristic of multiple system atrophy-cerebellar type. Journal of Neuroimmunology, 2020, 349, 577395.	2.3	5
230	Two susceptible HLA-DRB1 alleles for multiple sclerosis differentially regulate anti-JC virus antibody serostatus along with fingolimod. Journal of Neuroinflammation, 2020, 17, 206.	7.2	5
231	Rapidly spreading seizures arise from large-scale functional brain networks in focal epilepsy. Neurolmage, 2021, 237, 118104.	4.2	5
232	Long-Term Effect of Acetylcholinesterase Inhibitors on the Dorsal Attention Network of Alzheimer's Disease Patients: A Pilot Study Using Resting-State Functional Magnetic Resonance Imaging. Frontiers in Aging Neuroscience, 2022, 14, 810206.	3.4	5
233	Campylobacter jejuni DNA-binding protein from starved cells in Guillain–Barré syndrome patients. Journal of Neuroimmunology, 2011, 240-241, 74-78.	2.3	4
234	Decreased <scp>CCR</scp> 2 and <scp>CD</scp> 62 <scp>L</scp> expressions on peripheral blood classical monocytes in amyotrophic lateral sclerosis. Clinical and Experimental Neuroimmunology, 2014, 5, 92-96.	1.0	4

#	Article	IF	CITATIONS
235	Natalizumab for Achieving Relapse-Free, T1 Gadolinium-Enhancing-Lesion-Free, and T2 Lesion-Free Status in Japanese Multiple Sclerosis Patients: A Phase 2 Trial Subanalysis. Neurology and Therapy, 2017, 6, 153-159.	3.2	4
236	Calcium pyrophosphate dihydrate crystal deposition disease of the spinal dura mater: a case report. BJR case Reports, 2018, 4, 20170049.	0.2	4
237	Upregulation of Vesicular Glutamate Transporter 2 and STAT3 Activation in the Spinal Cord of Mice Receiving 3,3′-Iminodipropionitrile. Neurotoxicity Research, 2018, 33, 768-780.	2.7	4
238	Mitochondrial dysfunction and altered ribostasis in hippocampal neurons with cytoplasmic inclusions of multiple system atrophy. Neuropathology, 2018, 38, 361-371.	1.2	4
239	Temporal Trends in Clinical Characteristics and Door-to-Needle Time in Patients Receiving Intravenous Tissue Plasminogen Activator: A Retrospective Study of 4 Hospitals in Japan. Journal of Stroke and Cerebrovascular Diseases, 2019, 28, 104305.	1.6	4
240	Higher postictal parasympathetic activity following greater ictal heart rate increase in right-than left-sided seizures. Epilepsy and Behavior, 2019, 97, 161-168.	1.7	4
241	A case of overlapping adultâ€onset linear scleroderma and Parryâ€Romberg syndrome presenting with widespread ipsilateral neurogenic involvement. Neuropathology, 2020, 40, 109-115.	1.2	4
242	Early recurrent ischemic events after mechanical thrombectomy: effect of post-treatment intracranial hemorrhage. Journal of Neurology, 2021, 268, 2810-2820.	3.6	4
243	Induction of Chronic Inflammatory Arthropathy and Mesenchymal Tumors in Rats Infected With HTLV-I. Journal of Acquired Immune Deficiency Syndromes, 1997, 16, 380-392.	0.3	4
244	Focal Brain Lesions in Acquired Immunodeficiency Syndrome: DNA Diagnosis and Further Monitoring. Internal Medicine, 1999, 38, 521-521.	0.7	3
245	Clinical disability progression and platelet GP IIb/IIIa values in patients with atopic myelitis. Journal of Neuroimmunology, 2012, 246, 108-112.	2.3	3
246	Alterations in chemokine receptor expressions on peripheral blood monocytes in multiple sclerosis and neuromyelitis optica. Clinical and Experimental Neuroimmunology, 2013, 4, 201-205.	1.0	3
247	Distinct cytokine and <scp>T</scp> helper cell profiles between patients with multiple sclerosis who had or had not received interferonâ€beta. Clinical and Experimental Neuroimmunology, 2014, 5, 321-327.	1.0	3
248	A case of adult-onset reducing body myopathy presenting a novel clinical feature, asymmetrical involvement of the sternocleidomastoid and trapezius muscles. Journal of the Neurological Sciences, 2014, 343, 206-210.	0.6	3
249	Morvan's syndrome and myasthenia gravis related to familial Mediterranean fever gene mutations. Journal of Neuroinflammation, 2016, 13, 68.	7.2	3
250	Clinical characteristics of atrial fibrillationâ€related cardioembolic stroke in patients aged 80 years or older. Geriatrics and Gerontology International, 2017, 17, 708-713.	1.5	3
251	The accumulation of advanced glycation end-products in a schizophrenic patient with a glyoxalase 1 frameshift mutation: An autopsy study. Schizophrenia Research, 2020, 223, 356-358.	2.0	3
252	Immunotherapyâ€refractory vacuolar myopathy with mucin deposition in scleromyxedema: A possible role of fibroblast growth factor 2. Neuropathology, 2020, 40, 492-495.	1.2	3

#	Article	IF	Citations
253	Contribution of cortical lesions to cognitive impairment in Japanese patients with multiple sclerosis. Scientific Reports, 2020, 10, 5228.	3.3	3
254	Serum Anti-oligodendrocyte Autoantibodies in Patients With Multiple Sclerosis Detected by a Tissue-Based Immunofluorescence Assay. Frontiers in Neurology, 2021, 12, 681980.	2.4	3
255	Elevated mycobacterium avium subsp. paratuberculosis (MAP) antibody titer in Japanese multiple sclerosis. Journal of Neuroimmunology, 2021, 360, 577701.	2.3	3
256	Deficiency of MTH1 and/or OGG1 increases the accumulation of 8-oxoguanine in the brain of the AppNL-G-F/NL-G-F knock-in mouse model of Alzheimer's disease, accompanied by accelerated microgliosis and reduced anxiety-like behavior. Neuroscience Research, 2022, 177, 118-134.	1.9	3
257	MS: prevention of neural damage by early intervention. Lancet Neurology, The, 2008, 7, 3-5.	10.2	2
258	A deficit of dorsal stream function in patients with mild cognitive impairment and Alzheimer's disease. , 2012, , .		2
259	Multimodality evoked potentials for discrimination of atopic myelitis and multiple sclerosis. Clinical and Experimental Neuroimmunology, 2013, 4, 29-35.	1.0	2
260	Bacterial infectious burden and prevalence of idiopathic central nervous system demyelinating diseases in Japanese. Clinical and Experimental Neuroimmunology, 2013, 4, 351-352.	1.0	2
261	Case of chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids showing features common to multiple sclerosis. Clinical and Experimental Neuroimmunology, 2013, 4, 104-106.	1.0	2
262	Distinct features of immunoglobulin G2 aquaporinâ€4 antibody carriers with neuromyelitis optica. Clinical and Experimental Neuroimmunology, 2015, 6, 154-158.	1.0	2
263	Multiphasic acute disseminated encephalomyelitis associated with atypical rubella virus infection. Multiple Sclerosis Journal, 2015, 21, 252-254.	3.0	2
264	Minocyclineâ€induced human herpesvirus 6 encephalomyelitis with drastically disseminated contrastâ€enhanced lesions. European Journal of Neurology, 2016, 23, e76-e77.	3.3	2
265	Immune-mediated spastic paraparesis accompanied with high titres of voltage-gated potassium channel complex antibodies and myokymia/fasciculation. Journal of the Neurological Sciences, 2016, 364, 133-135.	0.6	2
266	A case of multiple system atrophy-parkinsonian type with stuttering- and palilalia-like dysfluencies and putaminal atrophy. Journal of Fluency Disorders, 2018, 57, 51-58.	1.7	2
267	Elevated end-diastolic ratio of the common carotid artery due to cerebral arteriovenous malformation: Two case reports. Radiology Case Reports, 2018, 13, 917-920.	0.6	2
268	A Visual Task Management Application for Acute Ischemic Stroke Care. Frontiers in Neurology, 2019, 10, 1118.	2.4	2
269	Branchial myorhythmia in a case of systemic lupus erythematosus. Journal of the Neurological Sciences, 2020, 408, 116501.	0.6	2
270	Central nervous system-specific antinuclear antibodies in patients with multiple sclerosis. Journal of the Neurological Sciences, 2020, 409, 116619.	0.6	2

#	Article	IF	CITATIONS
271	iNOS is not responsible for RyR1ÂS-nitrosylation in mdx mice with truncated dystrophin. BMC Musculoskeletal Disorders, 2020, 21, 479.	1.9	2
272	Neuroinflammation in Neurological Disorders. Advances in Neurobiology, 2013, , 21-48.	1.8	2
273	Generation of CD4+ blastoid T cells in recipients of BP/IFA-sensitized spleen cells. Cellular Immunology, 1990, 128, 130-141.	3.0	1
274	Efficacy of Highâ€frequency Magnetic Stimulation of the Sacral Root in Patients with Urinary Incontinence Following a Radical Prostatectomy. LUTS: Lower Urinary Tract Symptoms, 2011, 3, 10-14.	1.3	1
275	Early inhibition of tumor necrosis factorâ€Î± and interleukinâ€6 in muscle tissue as a therapy for dystrophinopathy in <i>mdx</i> mice. Clinical and Experimental Neuroimmunology, 2014, 5, 371-377.	1.0	1
276	Nationwide Japanese survey shows the characteristic features of combined central and peripheral demyelination. Clinical and Experimental Neuroimmunology, 2015, 6, 214-215.	1.0	1
277	Multiple Sclerosis: Etiology and Mechanism, with Special Reference to Asians. , 2016, , 73-103.		1
278	Safety and efficacy response to interferon betaâ€1a therapy in Japanese patients with multiple sclerosis: Interim results of a postmarketing surveillance study. Clinical and Experimental Neuroimmunology, 2016, 7, 59-65.	1.0	1
279	Peripheral blood T cell subset characteristics of multiple sclerosis in remission phase correlate with annualized relapse rates. Clinical and Experimental Neuroimmunology, 2016, 7, 346-352.	1.0	1
280	HLA genotype and cortical lesions: Response to the letter from Spencer et al Multiple Sclerosis Journal, 2018, 24, 819-820.	3.0	1
281	Brainstem posterior reversible encephalopathy syndrome in a case with Guillain–Barré syndrome. Clinical and Experimental Neuroimmunology, 2019, 10, 267-271.	1.0	1
282	Cognition with magnetic resonance imaging findings and social activities in patients with multiple sclerosis in a Japanese cohort. Clinical and Experimental Neuroimmunology, 2019, 10, 41-48.	1.0	1
283	Antiâ€plexin D1 antibody–mediated neuropathic pain. Clinical and Experimental Neuroimmunology, 2020, 11, 48-52.	1.0	1
284	PON1 Q192R is associated with high platelet reactivity with clopidogrel in patients undergoing elective neurointervention: A prospective single-center cohort study. PLoS ONE, 2021, 16, e0254067.	2.5	1
285	Redefining use of MRI for patients with multiple sclerosis. Lancet Neurology, The, 2021, 20, 591-592.	10.2	1
286	Correlation of the symbol digit modalities test with the quality of life and depression in Japanese patients with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 57, 103427.	2.0	1
287	Research on idiopathic demyelinating disease of the central nervous system in Japan: Current status and future direction. Clinical and Experimental Neuroimmunology, 2013, 4, 1-1.	1.0	0
288	Shower embolismâ€like brain lesions in <scp>C</scp> hurg– <scp>S</scp> trauss syndrome. Clinical and Experimental Neuroimmunology, 2013, 4, 348-350.	1.0	0

#	Article	IF	CITATIONS
289	Neuro2013. Clinical and Experimental Neuroimmunology, 2013, 4, 243-245.	1.0	О
290	12th <scp>M</scp> ultiple <scp>S</scp> clerosis <scp>W</scp> orkshop in <scp>F</scp> ukuoka. Clinical and Experimental Neuroimmunology, 2013, 4, 82-86.	1.0	0
291	Protein kinase C†polymorphism rs2230500 does not confer disease susceptibility to multiple sclerosis or neuromyelitis optica. Clinical and Experimental Neuroimmunology, 2013, 4, 283-287.	1.0	0
292	Launch of new review/editing system forClinical and Experimental Neuroimmunology. Clinical and Experimental Neuroimmunology, 2013, 4, 3-4.	1.0	0
293	Expectations and concerns regarding emerging new diseaseâ€modifying drugs for multiple sclerosis: What can we expect in the future?. Clinical and Experimental Neuroimmunology, 2014, 5, 273-274.	1.0	O
294	First nationwide survey of hypertrophic pachymeningitis in Japan not only solves epidemiological questions, but also leads to the proposal of new questions. Clinical and Experimental Neuroimmunology, 2014, 5, 277-278.	1.0	O
295	Time to reâ€visit "Asian modification―of multiple sclerosis: Lessons from the Japanese fingolimod studies. Clinical and Experimental Neuroimmunology, 2014, 5, 1-1.	1.0	o
296	What we know and do not know about fingolimod: Outline and interpretation of results from the $\langle scp \rangle J \langle scp \rangle$ apanese fingolimod core and extension studies. Clinical and Experimental Neuroimmunology, 2014, 5, 10-18.	1.0	0
297	New opportunity to improve research and clinical practice of multiple sclerosis in Japan. Clinical and Experimental Neuroimmunology, 2014, 5, 1-1.	1.0	0
298	Award announcement from 1st MS Summer College in Fukuoka. Clinical and Experimental Neuroimmunology, 2014, 5, 72-72.	1.0	O
299	First Multiple Sclerosis Summer College in Fukuoka (2–3 August 2014) Molecular targeted therapy in multiple sclerosis: Bench to bedside and bedside to bench. Clinical and Experimental Neuroimmunology, 2014, 5, 54-61.	1.0	0
300	Holocord involvement with sparing of the peripheral white matter rim in longitudinally extensive spinal cord lesions of neuromyelitis optica. Clinical and Experimental Neuroimmunology, 2015, 6, 78-79.	1.0	O
301	Multimodal diagnostic approach for limbic encephalitis associated with antivoltageâ€gated potassium channel complex antibodies. Clinical and Experimental Neuroimmunology, 2015, 6, 318-320.	1.0	0
302	New development of immune-brain interaction research: A new opportunity for improving our research and clinical practice in neuroimmunology through the Asia-Pacific School of Neuroimmunology. Clinical and Experimental Neuroimmunology, 2015, 6, 341-342.	1.0	0
303	Multiphasic acute disseminated encephalomyelitis associated with atypical rubella virus infection $\hat{a} \in \text{``response to the letter from Wu et al. Multiple Sclerosis Journal, 2015, 21, 1089-1089.}$	3.0	0
304	Recurrent cerebellitis associated with primary Sj \tilde{A} gren's syndrome. Clinical and Experimental Neuroimmunology, 2016, 7, 183-184.	1.0	0
305	Clear detection of lower medullary lesions by threeâ€dimensional double inversion recovery imaging in a patient with neuromyelitis optica spectrum disorder. Clinical and Experimental Neuroimmunology, 2016, 7, 355-356.	1.0	0
306	Strong association of <i>de novo</i> deletionâ€type copy number variations at T cell receptor alpha and gamma loci with multiple sclerosis and neuromyelitis optica. Clinical and Experimental Neuroimmunology, 2016, 7, 5-6.	1.0	0

#	Article	IF	CITATIONS
307	Relationship between Th1 cells and astrocytic connexin 43 gap junctions in multiple sclerosis. Clinical and Experimental Neuroimmunology, 2017, 8, 101-102.	1.0	0
308	Extensive white matter pathology of longitudinally extensive myelitis in neuromyelitis optica. Clinical and Experimental Neuroimmunology, 2017, 8, 9-10.	1.0	0
309	Measurement Conditions of End-Diastolic Ratio of Common Carotid Arteries Alter Diagnostic Ability for Large Artery Intracranial Occlusive Disease. Journal of Stroke and Cerebrovascular Diseases, 2017, 26, 2421-2426.	1.6	0
310	A case of rhabdomyolysis after status epilepticus without stroke-like episodes in mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes. Clinical Neurology, 2017, 57, 400-401.	0.1	0
311	Reply to letter to the editor: Dimethyl fumarate for patients with neuromyelitis optica spectrum disorder by Pitarokoili and Gold. Multiple Sclerosis Journal, 2018, 24, 366-367.	3.0	0
312	Creutzfeldt–Jakob diseaseâ€like diffusionâ€weighted imaging hyperintensity paralleled with neuropsychiatric symptoms in a patient with limbic encephalitis associated with antiâ€voltageâ€gated potassium channel complex antibodies. Clinical and Experimental Neuroimmunology, 2019, 10, 204-206.	1.0	O
313	Recurrent rhombencephalomyelitis associated with allergen immunotherapy by mite antigen sublingual tablets. ENeurologicalSci, 2019, 15, 100190.	1.3	0
314	Multiple mtDNA deletions due to mitochondrion toxicity of antiâ€hepadnaviral drugs: Comments to the letter from J. Finsterer. Neuropathology, 2019, 39, 326-327.	1.2	0
315	Case of central nervous system inflammatory disease in late pregnancy. Clinical and Experimental Neuroimmunology, 2019, 10, 54-58.	1.0	0
316	Antiâ€plexin D1 antibodies are a novel biomarker for immuneâ€mediated neuropathic pain. Clinical and Experimental Neuroimmunology, 2019, 10, 7-8.	1.0	0
317	Double positivity for anti―N â€methyl―d â€aspartate receptor and antiâ€aquaporinâ€4 antibodies in a patient presenting with hypersomnolence, personality change, and reduced spontaneity. Clinical and Experimental Neuroimmunology, 2020, 11, 53-56.	1.0	O
318	Award Announcement from the 6th MS Summer College in Fukuoka. Clinical and Experimental Neuroimmunology, 2020, 11, 67-67.	1.0	0
319	Autoantibodyâ€mediated neuroinflammation and molecular neuropathology in demyelinating disorders. Clinical and Experimental Neuroimmunology, 2020, 11, 3-3.	1.0	O
320	Risk HLA-DRB1 alleles differentially influence brain and lesion volumes in Japanese patients with multiple sclerosis. Journal of the Neurological Sciences, 2020, 413, 116768.	0.6	0
321	A case of steroid-resistant lupus nephritis and successful treatment with chlorambucil. Japanese Journal of Clinical Immunology, 1982, 5, 159-166.	0.0	0
322	Journal of the Japanese Society of Internal Medicine, 2017, 106, 1812-1820.	0.0	0
323	Journal of the Japanese Society of Internal Medicine, 2020, 109, 1764-1774.	0.0	O
324	A Case of Cerebral Tuberculoma with Mild Posterior Cervical Pain as the Main Symptom Despite Extensive Brain Lesions. Internal Medicine, 2022, , .	0.7	0